Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
IPO Year: 2014
Exchange: NASDAQ
Website: soleno.life
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2024 | $70.00 | Buy | H.C. Wainwright |
| 5/10/2024 | $72.00 | Outperform | Robert W. Baird |
| 2/5/2024 | $93.00 | Overweight | Piper Sandler |
| 1/23/2024 | $63.00 | Buy | Stifel |
| 11/21/2023 | $40.00 | Buy | Guggenheim |
Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022) Soleno Intends to Submit a New Drug Application for DCCR in PWS Mid-Year 2024 Company to Host Conference Call and Webcast Today at 9:00 AM ET REDWOOD CITY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- September 26, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Di
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)
10-Q - SOLENO THERAPEUTICS INC (0001484565) (Filer)
8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)
8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)
S-8 - SOLENO THERAPEUTICS INC (0001484565) (Filer)
10-Q - SOLENO THERAPEUTICS INC (0001484565) (Filer)
8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)
424B5 - SOLENO THERAPEUTICS INC (0001484565) (Filer)
8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone
REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience. "Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board," said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. "His impressive track record, including in rare diseases, will b
H.C. Wainwright initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $70.00
Robert W. Baird initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $72.00
Piper Sandler initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $93.00
Stifel initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $63.00
Guggenheim resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $40.00
Oppenheimer resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $8.00
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. Details of the oral presentations are as follows: ESPE 2024 Title:Relaxation of Food Control Parameters Based on Improvements in the Food Safe Zone Questionnaire Occurs with Reduction of Hyperphagia in C
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Corporate Highlights New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) accepted by the U.S. Food and Drug Administration (FDA) and granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024. The FDA Review
REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET Event: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024Time: 8:00 AM GT A live audio webcast and replay of the Guggenheim and Jefferies events will be availab
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced with deep sadness the passing of former Chairman of the Board of Directors, Ernest Mario, Ph.D, at the age of 86 years. Dr. Mario served as the Soleno's (formerly Capnia's) Chairman from 2007 through August 2024. "On behalf of the Board of Directors and the entire Soleno family, we extend our deepest condolences to Dr. Mario's family," said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. "Dr. Mario's decades-long commitment to the develo
REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a regulatory update from the U.S. Food and Drug Administration (FDA). The FDA Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS). However, the Division's review team will continue to consider the potential need for an advisory committee meeting during thei
REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (dia
PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for DCCR for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. The FDA granted Priority Review for the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December
REDWOOD CITY, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 143,850 shares of common stock to six employees as an inducement for them entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $49.52 and $48.44 per share, which is eq
Ernest Mario, Ph.D. steps down as Chair for health reasons; Matthew Pauls, J.D., M.B.A. assumes role of Lead Independent Director Dawn Carter Bir, seasoned biotech executive with significant commercial and strategic expertise, joins the Board of Directors REDWOOD CITY, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced updates to its Board of Directors. Dawn Carter Bir, a seasoned biotechnology executive with over 30 years of industry executive leadership and strategic experience, has been appointed to Soleno's Board of Di
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Corporate Highlights Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Diazoxide Choline Extended-Release (DCCR) for the treatment of Prader-Willi Syndrome (PWS) in individuals four years and older who have hyperphagia.Closed on an approximately $158.7 million underwritten public offering of 3,450,000
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. The chipmaker giant has seen an astounding 186% surge since the end of May 2023, fueled by skyrocketing demand for chips in artificial intelligence development. Veteran Wall Street investor Ed Yardeni recently coined “Magnificent One” to differentiate Nvidia’s extraordinary performance from the Magnificent Seven. To illustrate the magnitude of Nvidia's market value increase, just a year ago, the company was valued at $1 trillion. Today, it boasts a staggering $2.8 trillion valuation, making it the third-largest company in the U.S. Nvidia’s curren
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024 in Boston, Massachusetts.
Oppenheimer analyst Leland Gershell maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and lowers the price target from $65 to $59.
Baird analyst Brian Skorney initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Outperform rating and announces Price Target of $72.
Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.37) by 59.46 percent.
Soleno has also granted the underwriters a 30-day option to purchase up to 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about May 7, 2024, subject to market conditions and the satisfaction of customary closing conditions
Soleno Therapeutics, Inc. (NASDAQ:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The public offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offeri
Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the comparison of results from the Company's Phase 3 placebo-controlled study (C601) and open-label extension study (C602) evaluating investigational, once-daily DCCR (Diazoxide Choline) Extended-Release tablets in patients with Prader-Willi syndrome (PWS), to data from the PATH for PWS (PATH) natural history study, in the Journal of Neurodevelopmental Disorders. The article, entitled, "Behavioral Changes in Patients with Prader-Willi Syndrome Receiving Diazoxide Choline Extended-Release Tablets Compa